FDA’s Marks: Global Regulatory Convergence Vital to Cell & Gene Therapy Oversight

At a Thursday ASGCT 2024 session, CBER Director Peter Marks made the case for a better, “more convergent” global framework on cell and gene therapies, especially for rare diseases.